Herceptin and Perjeta for gastric cancer – pro
HER2 is over-expressed in 10–25% of gastric cancers. The recent ToGA trial successfully demonstrated trastuzumab as the first biologic therapy to have activity in advanced gastric cancer. Currently pertuzumab, a novel HER2-targeting agent is under investigation in gastric cancer. Pertuzumab activates antibody-dependent cellular cytotoxicity (ADCC) and has a major effect on the role of HER2 as a co-receptor for HER3 or EGFR, thus inhibiting multiple HER-mediated signaling pathways, and there is a suggestion in xenograft studies that these two drugs are synergistic. . The combination of Perjeta and Herce[tn is not recommended by guidelines or supported by guidelines even in HER+ gastric cancer and ti si currently in a clinical study: JACOB Study Pertuzumab With Trastuzumab and Chemotherapy in Patients With HER2+ Metastasic Gastric and Gastroesophageal Cancer In NCT01774786.
Krishna S. Gunturu, Yanghee Woo, Nike Beaubier, Helen E. Remotti, and M. Wasif Saif, Gastric cancer and trastuzumab: first biologic therapy in gastric cancer, Ther Adv Med Oncol. 2013 Mar; 5(2): 143–151.
M. Martin-Richard et al,Some guidelines for the treatment of gastric cancer 2015, Clin Transl Oncol. 2015; 17: 996–1004.